Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextrose monohydrate + magnesium chloride + sodium lactate + calcium chloride + sodium chloride is a **peritoneal dialysis solution** marketed as **DIANEAL PD-2 with Dextrose** by Vantive US Healthcare for intraperitoneal use in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. It is a hypertonic, pharmacologically inactive multicomponent small-molecule solution in which **dextrose** acts as the principal osmotic agent, generating an osmotic gradient across the peritoneal membrane to promote transcapillary ultrafiltration and removal of water and solutes, while **sodium, calcium, magnesium, chloride, and lactate** provide electrolyte and buffer support. The product is indicated for management of **acute kidney injury** and **chronic kidney disease** requiring peritoneal dialysis, and notable risks described for this product class include **peritonitis** and **encapsulating peritoneal sclerosis**; it is contraindicated in severe lactic acidosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose monohydrate + magnesium chloride + sodium lactate + calcium chloride + sodium chloride.